Artificial intelligence in COVID-19 drug repurposing.

Journal: The Lancet. Digital health
PMID:

Abstract

Drug repurposing or repositioning is a technique whereby existing drugs are used to treat emerging and challenging diseases, including COVID-19. Drug repurposing has become a promising approach because of the opportunity for reduced development timelines and overall costs. In the big data era, artificial intelligence (AI) and network medicine offer cutting-edge application of information science to defining disease, medicine, therapeutics, and identifying targets with the least error. In this Review, we introduce guidelines on how to use AI for accelerating drug repurposing or repositioning, for which AI approaches are not just formidable but are also necessary. We discuss how to use AI models in precision medicine, and as an example, how AI models can accelerate COVID-19 drug repurposing. Rapidly developing, powerful, and innovative AI and network medicine technologies can expedite therapeutic development. This Review provides a strong rationale for using AI-based assistive tools for drug repurposing medications for human disease, including during the COVID-19 pandemic.

Authors

  • Yadi Zhou
    Department of Chemistry and Biochemistry , Ohio University , Athens , Ohio 45701 , United States.
  • Fei Wang
    Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, NY, United States.
  • Jian Tang
    Department of Decision Sciences HEC, Université de Montréal, Montreal, Québec, Canada.
  • Ruth Nussinov
    Computational Structural Biology Section, Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702, USA.
  • Feixiong Cheng
    Genomic Medicine Institute, Lerner Research Institute , Cleveland Clinic , Cleveland , Ohio 44106 , United States.